Quad Asset Management
VC Fund
Quad Asset Management is an Investment firm.
- Total investments:
- 45
- Last investment:
- Lead investor:
- 2%
Last updated:
For AI agents: llms.txt
Industries Quad Asset Management invests in
Stages Quad Asset Management invests in
Countries Quad Asset Management invests in
Round sizes
Round size
- Series A
- $4.4M–$15M
- Series B
- $4.5M–$42M
- Series C
- $9.2M–$33M
Investment Focus
Industry
- Biotechnology 13 (29%)
- Pharmaceutical 8 (18%)
- Medical 7 (16%)
- Health Care 6 (13%)
- Artificial Intelligence 6 (13%)
Stage
- Series B 11 (24%)
- Series A 10 (22%)
- Series C 5 (11%)
- Funding Round 2 (4%)
- Seed 1 (2%)
Country
- South Korea 25 (56%)
- United States 1 (2%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Nventric
|
Nventric is a medical device company that develops core products for neurovascular, coronary heart, and peripheral vascular applications. | $22.6M / Venture - Series Unknown / Jun 10, 2026 | |
Mediwhale
|
Medi Whale seeks to achieve sustainable healthcare where every eye can truly be the window to one’s health with our world's first-of-its-kind 1-stop AI screening platform solution for cardiovascular, renal, metabolic risk assessment, and eye disease diagnosis. Our AI Platform was developed through several clinical collaborations (Korea,Singapore, India, UK, and other European datasets) using structured longitudinal event-based datasets for the development of our retinal biomarker engines. RetiCVD® (cardiovascular disease risk assessment): Developed using coronary artery calcium (CAC) score, CAC is recognized as the gold standard for precise CVD risk calculation. Our CVD engine predicts the presence of CAC and provides a stratified probabilistic risk based on US ASCVD and EU SCORE guidelines.RetiCKD® (chronic kidney disease risk assessment): Developed using eGFR and full lab panel, our CKD engine has been demonstrated to achieve better predictive capability as compared to eGFR or full panel analysis.RetiEYE®: Referable Eye Disease engine detects and flags common aging-related eye modalities such as diabetic retinopathy, age-related macular degeneration, glaucoma, and cataract at its referable disease state.Medi Whale retinal-based systemic biomarkers have been clinically demonstrated to be non-inferior to current gold standards and are recognized by clinical and scientific communities with two Lancet Digital Health publications. | $13.3M / Series C / Mar 27, 2026 | |
IMBiologics
|
IMBiologics is a biotechnology company that develops antibody-based drug candidates for diseases such as cancer and immune-related conditions. It conducts research and development using its own platforms to discover new therapeutic molecules. | $29.5M / Series C / Oct 14, 2025 | |
Nex Eye
|
Nex Eye is an innovative biotechnology firm that offers revolutionary immunotherapy solutions for individuals battling cancer. The company addresses the fundamental reasons behind the failure of immunotherapy, which are influenced by the biology of cancer itself. Utilizing its ON-SMRT® platform based on actual patient data and resistant cancermodels, Nex Eye identifies new immune-evasion targets such as ONCOKINE®. By transforming the approach to tackling immune resistance, the firm is pioneering a new era in cancer therapy by revitalizing the capabilities of the immune system. | $44.2M / Series B / Aug 13, 2025 | |
EverEx
|
EverEx is a software-based therapeutics company specialized on musculoskeletal disorders with an AI-enabled pose estimation. | $10.6M / Series B / Jul 31, 2025 | |
Illimis Therapeutics
|
Illimis Therapeutics is a platform-based biotech company that develops a chimeric fusion protein platform for neurodegenerative diseases. The company's proprietary GAIA (Gas6-mediated Anti-Inflammatory Adaptor) platform is designed to harness the therapeutic potential of TAM (Tyro3, Axl, Mer) receptor biology, a critical pathway involved inregulating inflammation and immune responses. | $41.9M / Series B / Jul 14, 2025 | |
Prazer Therapeutics
|
Prazer Therapeutics assists patients suffering from intractable diseases through the use of logical and innovative drug design approaches. They willaccomplished this through the use of new and innovative drug development platforms, such as rational molecular drug design technology and next-generation protein degradation technology. | $19.7M / Series B / Apr 01, 2025 | |
Ubix Therapeutics
|
Ubix Therapeutics is a research and development company that develops anti-cancer drugs. | $17.7M / Series C / Dec 23, 2024 | |
AIGEN Sciences
|
AIGEN Sciences is an AI drug discovery platform that provides drug research and development services. | $8.8M / Series A / Oct 16, 2024 | |
Cubixel
|
Cubixel is a developer of optical inspection equipment that has been successfully commercialized for use in the medical and biotech industries. The firm focuses on creating high-speed FSH (flying-over scanning holography) camera technology, which employs optical holographic inspection tools to obtain 3D images in one go. This groundbreakingtechnology enables clients to effortlessly capture and apply 3D images within their specific industries. | $12.7M / Venture - Series Unknown / Sep 06, 2024 | |
| See all 45 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Quad Asset Management invest in?
Quad Asset Management invests primarily in Biotechnology, Pharmaceutical and Medical startups, most often at Series B and Series A stage. Most of the 45 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Quad Asset Management's check size?
Quad Asset Management typically joins rounds of $4.4M–$15M at Series A, $4.5M–$42M at Series B and $9.2M–$33M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Quad Asset Management participates in.
When did Quad Asset Management last invest?
The most recent investment recorded for Quad Asset Management closed in Jun 2026. Shizune tracks 45 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
